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Abstract
Soybean DAS-81419-2 was developed by Agrobacterium tumefaciens-mediated transformation. It expresses
the Cry1F and Cry1Ac proteins to confer resistance to certain lepidopteran species and the PAT protein that
confers tolerance to glufosinate ammonium-based herbicides and that was used as a selectable marker gene.
The molecular characterisation of soybean DAS-81419-2 did not give rise to safety issues. The agronomic,
phenotypic and compositional characteristics of soybean DAS-81419-2 tested under ﬁeld conditions revealed
no relevant differences between soybean DAS-81419-2 and its conventional counterpart that would give rise
to any food and feed or environmental safety concerns. There were no concerns regarding the potential
toxicity and allergenicity of the newly expressed proteins Cry1F, Cry1Ac and PAT, and no evidence that the
genetic modiﬁcation might signiﬁcantly change the overall allergenicity of soybean DAS-81419-2. The
nutritional value of soybean DAS-81419-2 is not expected to differ from that of non-GM soybean varieties
and no post-market monitoring of food/feed is considered necessary. There are no indications of an
increased likelihood of establishment and spread of occasional feral soybean DAS-81419-2 plants, unless
these plants are exposed to glufosinate ammonium-based herbicides or infested by insect pests that are
susceptible to the Cry1F and Cry1Ac proteins. This will not result in different environmental impacts
compared to conventional soybean. Considering the scope of this application, interactions with the biotic and
abiotic environment were not considered to be an issue. Risks associated with an unlikely but theoretically
possible horizontal gene transfer from soybean DAS-81419-2 to bacteria have not been identiﬁed. The
post-market environmental monitoring plan and reporting intervals are in line with the intended uses of
soybean DAS-81419-2. The GMO Panel concludes that the soybean DAS-81419-2 is as safe and as nutritious
as its conventional counterpart and the tested non-GM reference varieties in the context of its scope.
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Summary
Following the submission of an application (EFSA-GMO-NL-2013-116) under Regulation (EC)
No 1829/20031 from Dow AgroSciences LLC, the EFSA Panel on Genetically Modiﬁed Organisms (GMO
Panel) was asked to deliver a scientiﬁc opinion on the safety of insect-resistant genetically modiﬁed
(GM) soybean (Glycine max L.) DAS-81419-2 (Unique Identiﬁer DAS-81419-2). The scope of application
EFSA-GMO-NL-2013-116 is for import, processing, and food and feed uses of soybean DAS-81419-2
within the European Union (EU), but it excludes cultivation in the EU. Soybean DAS-81419-2 expresses
Cry1F and Cry1Ac proteins which confer resistance to lepidopteran insect pests. Soybean DAS-81419-2
also expresses the pat gene producing the PAT protein that confers tolerance to glufosinate ammonium-
based herbicides and that was used as a selectable marker gene only. Therefore, in line with the scope
of the application, the tolerance to glufosinate ammonium-based herbicides was not assessed in the
comparative analyses.
The GMO Panel evaluated soybean DAS-81419-2 with reference to the scope and appropriate
principles described in its guidelines for the risk assessment of GM plants. The evaluation addressed
the following components of the risk assessment: the molecular characterisation of the inserted DNA
and analysis of the expression of the corresponding proteins; the comparative analyses of
compositional, agronomic and phenotypic characteristics; the safety of the newly expressed proteins
and the whole food/feed with respect to potential toxicity, allergenicity and nutritional characteristics;
and the environmental risk assessment and the post-market environmental monitoring plan (PMEM).
Soybean DAS-81419-2 was developed by Agrobacterium tumefaciens (also known as
Rhizobium radiobacter)-mediated transformation of cotyledonary nodes derived from germinated
soybean (G. max) cv. Maverick seeds. It expresses the Cry1F and Cry1Ac proteins which confer
resistance to lepidopteran insect pests. Soybean DAS-81419-2 also produces the PAT protein which
confers tolerance to glufosinate ammonium-based herbicides and was used as a selectable marker during
product development. The molecular characterisation data established that soybean DAS-81419-2
contains a single insert consisting of the cry1Fv3, cry1Ac (synpro) and pat expression cassettes
producing the Cry1F, Cry1Ac and the PAT proteins. No other parts of the plasmid used for transformation
were detected in soybean DAS-81419-2. Bioinformatic analyses and genetic stability studies were
performed and the results did not give rise to safety issues. The levels of the newly expressed proteins
present in soybean DAS-81419-2 were obtained and reported adequately. The protein characterisation
data comparing the structural, biochemical and functional properties of plant and microbial derived
Cry1F, Cry1Ac and PAT proteins, indicate that these proteins are equivalent.
Based on the agronomic and phenotypic characteristics of soybean DAS-81419-2 tested under ﬁeld
conditions, none of the differences identiﬁed between soybean DAS-81419-2 and its conventional
counterpart required further assessment, except for ‘100 seed weight’. Additionally, no relevant
differences were observed between soybean DAS-81419-2 and its conventional counterpart with
regard to seed germination when tested under controlled conditions.
The safety assessment identiﬁed no concerns regarding the potential toxicity and allergenicity of
the proteins Cry1F, Cry1Ac and PAT, newly expressed in soybean DAS-81419-2, and found no evidence
that the genetic modiﬁcation might signiﬁcantly change the overall allergenicity of soybean DAS-
81419-2, when compared with that of its conventional counterpart and non-GM commercial reference
soybean varieties. Based on the outcome of the comparative assessment, the nutritional value of food
and feed derived from soybean DAS-81419-2 is not expected to differ from that of food and feed
derived from non-GM soybean varieties. The GMO Panel considers that post-market monitoring of
food/feed derived from soybean DAS-81419-2 is not necessary, given the absence of safety concerns
identiﬁed. Application EFSA-GMO-NL-2013-116 covers the import, processing, and food/feed uses of
soybean DAS-81419-2, excluding cultivation. Therefore, the environmental risk assessment is
concerned with the accidental release into the environment of viable soybean DAS-81419-2 seeds
(i.e. during transport and/or processing), and with the exposure of bacteria to recombinant DNA in the
gastrointestinal tract of animals fed GM material and those present in environments exposed to their
faecal material (manure and faeces).
Due to the low survival capacity of soybean, the observed difference in ‘100 seed weight’ is unlikely
to change the ﬁtness (e.g. survival, fecundity, competitiveness) or invasiveness characteristics of
soybean DAS-81419-2 plants. In the case of accidental release into the environment of viable seeds of
soybean DAS-81419-2, there are no indications of an increased likelihood of establishment and spread
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
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of occasional feral soybean DAS-81419-2 plants, unless these plants are exposed to glufosinate
ammonium-based herbicides or infested by insect pests that are susceptible to the Cry1F and Cry1Ac
proteins. However, the GMO Panel is of the opinion that the latter will not result in different
environmental impacts compared to conventional soybean. Considering the scope of the application
EFSA-GMO-NL-2013-116, interactions with the biotic and abiotic environment are not considered to be
relevant issues. Bioinformatic analysis of the inserted DNA identiﬁed sufﬁcient sequence identity with
bacterial DNA which could theoretically facilitate the transfer of a plant codon-optimised cry gene and
a pat gene onto a plasmid of a soil bacterium. Based on the functional proteins encoded by the genes
and the prevalence of natural variants of such genes in environmental bacterial communities, the GMO
panel did not identify a concern in relation to horizontal gene transfer to bacteria. Therefore,
considering the introduced traits, the outcome of the comparative analysis, the routes of exposure and
the limited exposure levels, the GMO Panel concludes that soybean DAS-81419-2 would not raise
safety concerns in the event of accidental release of viable GM soybean seeds into the environment.
The PMEM plan provided by the applicant and the reporting intervals are in line with the intended uses
of soybean DAS-81419-2 and the GMO Panel guidelines on the PMEM of GM plants.
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-NL-2013-116,
additional information provided by the applicant, scientiﬁc comments submitted by the Member States
and relevant scientiﬁc publications. In conclusion, the GMO Panel considers that the information available
for soybean DAS-81419-2 addresses the scientiﬁc comments raised by the Member States and that
soybean DAS-81419-2, as described in this application and under current processing procedures, is as
safe and nutritious as its conventional counterpart and the tested non-GM soybean reference varieties
with respect to potential effects on human and animal health and the environment in the context of the
scope of this application.
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1. Introduction
The scope of application EFSA-GMO-NL-2013-116 is for import, processing, and food/feed uses of
soybean DAS-81419-2 derived from grain and forage and does not include cultivation in the European
Union (EU).2
Soybean DAS-81419-2 was developed to confer resistance to certain lepidopteran chewing pests. The
resistance is achieved by the expression of the Cry1F and Cry1Ac proteins from Bacillus thuringiensis.
Soybean DAS-81419-2 also expresses the PAT protein from Streptomyces viridochromogenes, that
confers tolerance to glufosinate ammonium-based herbicides and that was used as a selectable marker
gene.3
1.1. Background
On 13 May 2013, the European Food Safety Authority (EFSA) received from the Competent
Authority of the Netherlands an application (Reference EFSA-GMO-NL-2013-116) for authorisation of
GM soybean DAS-81419-2 (unique identiﬁer DAS-81419-2), submitted by Dow AgroSciences LLC within
the framework of Regulation (EC) No 1829/2003 on GM food and feed.
After receiving the application EFSA-GMO-NL-2013-116, and in accordance with Articles 5(2)(b) and
17(2)(b) of the Regulation (EC) No 1829/2003, EFSA informed the Member States and the European
Commission, and made the summary of the application publicly available on the EFSA website.4 EFSA
initiated a formal review of the application to check compliance with the requirements laid down in
Articles 5(3) and 17(3) of the Regulation (EC) No 1829/2003. On 21 November 2013 and 17 January
2014, EFSA received additional information requested under completeness check 25 June 2013 and 12
December, respectively. On 7 February 2014, EFSA declared the application as valid in accordance with
Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003.
EFSA made the valid application available to the Member States and the European Commission, and
consulted nominated risk assessment bodies of the Member States, including national Competent
Authorities within the meaning of Directive 2001/18/EC5 following the requirements of Articles 6(4)
and 18(4) of Regulation (EC) No 1829/2003, to request their scientiﬁc opinion. The Member States
had 3 months after the date of receipt of the valid application (until 27 May 2014) to make their
opinion known.
On 12 February 2014 and 25 April 2016 (European Union Reference Laboratories-Joint Research
Centre (EURL-JRC)), 8 April 2014, 28 May 2014, 23 June 2014, 9 September 2014, 1 October 2015, 23
November 2015, 17 February 2016, 15 March 2016, 26 May 2016, 10 June 2016 and 10 August 2016,
the EFSA Panel on Genetically Modiﬁed Organisms (GMO Panel) requested additional information from
the applicant. The applicant provided the requested information on 20 February 2014 and 7
September 2016 (EURL-JRC), 18 June 2014, 27 August 2014, 12 November 2014, 25 November 2014,
24 November 2015, 18 January 2016, 7 March 2016, 29 March 2016, 13 June 2016, 17 June 2016 and
1 September 2016. The applicant also spontaneously provided additional information on 16 December
2014, 18 January 2016, 22 January 2016 and 31 March 2016.
In giving its scientiﬁc opinion on soybean DAS-81419-2 to the European Commission, the Member
States and the applicant, and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003,
EFSA has endeavoured to respect a time limit of 6 months from the acknowledgement of the valid
application. As additional information was requested by the GMO Panel, the time limit of 6 months was
extended accordingly, in line with Articles 6(1), 6(2), 18(1) and 18(2) of Regulation (EC) No 1829/2003.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
1.2. Terms of Reference as provided by the requestor
The EFSA GMO Panel was requested to carry out a scientiﬁc assessment of soybean DAS-81419-2
for food and feed uses, import and processing in accordance with Articles 6(6) and 18(6) of Regulation
(EC) No 1829/2003.
2 Additional information: 22/1/2016.
3 Dossier: Part II – Section A2.
4 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2013-00527
5 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
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Where applicable, any conditions or restrictions which should be imposed on the placing on the
market and/or speciﬁc conditions or restrictions for use and handling, including post-market monitoring
requirements based on the outcome of the risk assessment and, in the case of genetically modiﬁed
organisms (GMOs) or food/feed containing or consisting of GMOs, conditions for the protection of
particular ecosystems/environment and/or geographical areas should be indicated in accordance with
Articles 6(5)(e) and 18(5)(e) of Regulation (EC) No 1829/2003.
The GMO Panel was not requested to give an opinion on information required under Annex II to
the Cartagena Protocol. Furthermore, the GMO Panel did not consider proposals for labelling and
methods of detection (including sampling and the identiﬁcation of the speciﬁc transformation event in
the food/feed and/or food/feed produced from it), which are matters related to risk management.
2. Data and methodologies
2.1. Data
In delivering its scientiﬁc opinion, the EFSA Panel took into account application EFSA-GMO-NL-2013-116,
additional information provided by the applicant, scientiﬁc comments submitted by the Member States
and relevant scientiﬁc publications.
2.2. Methodologies
The GMO Panel carried out a scientiﬁc risk assessment of soybean DAS-81419-2 for food and feed
uses, import and processing in accordance with Articles 6(6) and 18(6) of Regulation (EC) No 1829/2003.
The GMO Panel took into account the appropriate principles described in its guidelines for the risk
assessment of genetically modiﬁed (GM) plants and derived food and feed (EFSA GMO Panel, 2011a), for
the environmental risk assessment (ERA) of GM plants (EFSA GMO Panel, 2010a) and for the post-market
environmental monitoring (PMEM) of GM plants (EFSA GMO Panel, 2011b).
The comments raised by the Member States are addressed in Annex G of EFSA’s overall opinion4
and were taken into consideration during the scientiﬁc risk assessment.
3. Assessment
3.1. Molecular characterisation
3.1.1. Evaluation of relevant scientiﬁc data
3.1.1.1. Transformation process and vector constructs
Soybean DAS-81419-2 was developed by Agrobacterium tumefaciens (also known as
Rhizobium radiobacter)-mediated transformation of cotyledonary nodes of soybean (Glycine max (L.)
Merr.) variety Maverick with the A. tumefaciens strain EHA101 containing the binary plasmid
pDAB9582. The transfer-deoxyribonucleic acid (T-DNA) present in plasmid pDAB9582 consisted of the
following elements between their respective right and left border (border A and B, respectively)
regions: partial MAR (matrix attachment region) sequence from Nicotiana tabacum rb-7-5A gene;
AtUbi10 promoter, 50 untranslated region (UTR) and intron from Arabidopsis thaliana polyubiquitin 10
(UBQ10) gene to direct constitutive expression; synthetic cry1Fv3 coding sequence producing the
chimeric Cry1F protein and consisting of parts of the cry1Fa2 and cry1Ca3 genes from B. thuringiensis
subsp. aizawai strain PS811 and part of the cry1Ab1 gene from B. thuringiensis subsp. berliner strain
1715; 30 UTR of the open reading frame (ORF) 23 from the A. tumefaciens plasmid pTi15955 that
terminates transcription and directs polyadenylation; promoter and 50 UTR from Cassava vein mosaic
virus (CsVMV) to drive constitutive expression; synthetic cry1Ac (synpro) coding sequence producing
the chimeric Cry1Ac protein and consisting of a part of the cry1Ac1 gene from B. thuringiensis subsp.
kurstaki strain HD73, part of the cry1Ca3 gene from B. thuringiensis subsp. aizawai strain PS811 and
part of the cry1Ab1 gene from B. thuringiensis subsp. berliner strain 1715; 30 UTR of the AtuORF23
from the A. tumefaciens plasmid pTi15955 that terminates transcription and directs polyadenylation;
promoter and 50 UTR from CsVMV to direct constitutive expression; a pat coding sequence from
S. viridochromogenes; 30 UTR of the AtuORF1 from the A. tumefaciens plasmid pTi15955 that
terminates transcription and directs polyadenylation.
Additional functional elements in the plasmid vector outside the T-DNA, and thus not expected to
be transferred to the soybean genome, were: ori origin of replication from broad host range RK2
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plasmid, for the maintenance of pDAB9582 in bacteria; trfA from the RK2 plasmid serving as
replication initiator; SpecR bacterial selectable marker gene from Escherichia coli Tn7 transposon to
confer spectinomycin resistance.
3.1.1.2. Transgene constructs in the GM plant
Molecular characterisation of soybean DAS-81419-2 was performed by Southern analysis,
polymerase chain reaction (PCR) and DNA sequence analysis, in order to determine insert copy
number, size and organisation of the inserted sequences and to conﬁrm the absence of plasmid
backbone sequences.6 The approach used was acceptable both in terms of coverage and sensitivity.
Southern analyses indicated that soybean DAS-81419-2 contains a single insert, which consists of a
single copy of the T-DNA in the same conﬁguration as in the pDAB9582 vector. The insert and copy
number were conﬁrmed by multiple restriction enzyme/probe combinations covering the T-DNA region
and ﬂanking regions. PCR analyses conﬁrmed the results obtained by Southern analyses. The absence
of vector backbone sequences was demonstrated by Southern analysis using backbone-speciﬁc
overlapping probes.
The nucleotide sequence of the entire insert of soybean DAS-81419-2 together with 1,297 bp of
the 50 and 1,379 bp of the 30 ﬂanking regions were determined. The insert of 12,496 bp is identical to
the T-DNA of pDAB9582, except for the deletion of 23 bp and 408 bp of the 50 and 30 border regions,
respectively. In addition, 37 bp of ﬁller DNA and a 98 bp fragment of cry1Ac (synpro) were inserted at
the 50 junction and 9 bp of ﬁller DNA were inserted at the 30 junction of the insert during the
integration process. A comparison with the pre-insertion locus indicated that 57 bp were deleted from
soybean genomic DNA. The possible interruption of known endogenous soybean genes by the
insertion in event DAS-81419-2 was evaluated by bioinformatic analyses of the pre-insertion locus and
of the genomic sequences ﬂanking the insert. The results from these analyses did not indicate the
interruption of any known endogenous gene in soybean DAS-81419-2.7
The results of segregation (see below) and bioinformatic analyses established that the insert is
located in the nuclear genome.
Updated bioinformatic analyses of the amino acid sequences of the three newly expressed proteins
Cry1F, Cry1Ac and PAT revealed no signiﬁcant similarities to toxins and allergens.7 In addition, updated
bioinformatics analyses of the newly created ORFs within the inserts and at their junctions indicate
that the expression of an ORF showing signiﬁcant similarities to toxins or allergens is highly unlikely.7
In order to assess the possibility for horizontal gene transfer (HGT) by homologous recombination
(HR), the applicant performed a sequence identity analysis of the regions of bacterial origin in soybean
DAS-81419-29. Three elements were identiﬁed with sufﬁcient length and identity to support HR
(de Vries and Wackernagel, 2002; Monier et al., 2007; H€ulter and Wackernagel, 2008; EFSA, 2009;
Overballe-Petersen et al., 2013), namely a 709 bp fragment of A. tumefaciens Ti plasmid pTi15955
containing the 30 untranslated region of AtuORF1 and two fragments of 526 and 457 bp, respectively,
from the same plasmid and containing the 30 untranslated region of AtuORF23. A double HR event
involving these sequences and the Ti plasmid of A. tumefaciens is a possible scenario to consider.
The likelihood and potential consequences of plant-to-bacteria gene transfer are described in
Section 3.4.1.1.
3.1.1.3. Protein characterisation and equivalence
Soybean DAS-81419-2 expresses three new proteins, Cry1F, Cry1Ac and PAT
Given the technical restraints in producing large enough protein quantities for safety testing from
plants, these proteins were recombinantly produced in microbes, Pseudomonas ﬂuorescens or E. coli.
Prior to safety studies, a panel of biochemical methods were employed to demonstrate the equivalence
between soybean and microbe-derived proteins. Puriﬁed proteins from these sources were
characterised and compared in terms of their physicochemical, structural and functional properties.8,9
Cry1F characterisation and equivalence. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and western blot analysis showed that full-length plant and microbe-derived Cry1F
proteins had the expected molecular weight of ~ 130 kDa and were comparably immunoreactive to
Cry1F protein speciﬁc antibodies. Glycosylation detection analysis demonstrated that none of the Cry1F
6 Dossier: Part II – Section A2.1.
7 Additional information: 18/1/2016.
8 Additional information: 29/3/2016.
9 Dossier: Part II – Section A4.2.
Scientiﬁc opinion on GM soybean DAS-81419-2
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2016;14(12):4642
proteins were N-glycosylated. Amino acid sequence analysis by mass spectrometry methods showed
that both proteins matched their expected sequence. Functional equivalence was demonstrated by an
insect feeding bioassay which showed that both proteins had comparable insecticidal activity.
Cry1Ac characterisation and equivalence. SDS-PAGE and western blot analysis showed that
full-length plant and microbe-derived Cry1Ac proteins had the expected molecular weight of ~ 130 kDa
and were comparably immunoreactive to Cry1Ac protein speciﬁc antibodies. Glycosylation detection
analysis demonstrated that none of the Cry1Ac proteins were N-glycosylated. Amino acid sequence
analysis by mass spectrometry methods showed that both proteins matched their expected sequence.
Functional equivalence was demonstrated by an insect feeding bioassay which showed that both
proteins had comparable insecticidal activity.
PAT characterisation and equivalence. SDS-PAGE and western blot analysis showed that plant and
microbe-derived PAT proteins had the expected molecular weight of ~ 20 kDa and were comparably
immunoreactive to PAT protein speciﬁc antibodies. Glycosylation detection analysis demonstrated that
none of the PAT proteins were N-glycosylated. Amino acid sequence analysis by mass spectrometry
methods showed that both proteins matched their expected sequence. Functional equivalence was
demonstrated by a biochemical in vitro activity assay which showed that both proteins had comparable
activity and speciﬁcity for the intended herbicide.
Based on this, the GMO Panel accepts the use of the Cry1F, Cry1Ac and PAT proteins derived from
P. ﬂuorescens or E. coli in the safety studies.
3.1.1.4. Information on the expression of the insert
Levels of the Cry1F, Cry1Ac and PAT proteins were analysed by enzyme-linked immunosorbent
assay (ELISA) in the leaf, root, forage and seed of soybean DAS-81419-2 in 2011 from 10 locations in
the USA.10 Considering the scope of the application, the Cry1F, Cry1Ac and PAT protein levels in seed
are considered the most relevant. The mean values and ranges of protein expression levels in seed
(n = 40) are summarised in Table 1.
3.1.1.5. Inheritance and stability of inserted DNA11
Genetic stability of the soybean DAS-81419-2 insert was assessed by Southern analysis of genomic
DNA from ﬁve different generations. The restriction enzyme/probe combinations used were sufﬁcient
to conclude that all the plants tested retained the single copy of the insert and ﬂanking regions, which
were stably inherited in subsequent generations.
Phenotypic stability was observed by segregation analysis, PAT protein expression and event-speciﬁc
PCR data. The results supported the presence of a single insertion, segregating in a Mendelian fashion.
3.1.2. Conclusion on molecular characterisation
The molecular characterisation data establish that soybean DAS-81419-2 contains a single insert
consisting of one copy of the Cry1Fv3, Cry1Ac (synpro) and pat expression cassettes producing the
Cry1F, Cry1Ac and PAT proteins, respectively. Bioinformatic analyses of the newly expressed proteins
and the ORFs within the insert or spanning the junction sites between the insert and genomic DNA did
not give rise to safety issues. The stability of the inserted DNA and of the introduced insect resistance
and herbicide tolerance traits were conﬁrmed over several generations. The levels of the Cry1F, Cry1Ac
and PAT proteins were obtained and reported adequately. The protein characterisation data comparing
the structural, biochemical and functional properties of plant and microbial derived Cry1F, Cry1Ac and
PAT proteins, indicate that these proteins are equivalent.
Table 1: Means, standard deviations and ranges of protein levels in (lg/g dry weight) from soybean
DAS-81419-2 seeds (number of samples is 40)
Tissue Cry1F Cry1Ac PAT
Seed 13.8(a)  1.24(b) 1.04  0.1 0.86  0.13
(10.41–16.95)(c) (0.79–1.40) (0.63–1.12)
(a): Mean.
(b): Standard deviation.
(c): Range.
10 Dossier: Part II – Section A2.2.3.
11 Dossier: Part II – Section A2.2.4.
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3.2. Comparative analyses
3.2.1. Evaluation of relevant scientiﬁc data
3.2.1.1. Choice of comparator and production of material for the comparative
assessment12
Application EFSA-GMO-NL-2013-116 presents data on agronomic and phenotypic characteristics, as
well as forage and seed composition of soybean DAS-81419-2 derived from ﬁeld trials performed at 11
sites in the USA in 2011 and 2012 (Table 2).
Field trials for the agronomic, phenotypic and compositional assessment of soybean DAS-81419-2
were conducted in major soybean growing areas of the USA,13 representing regions of diverse
agronomic practices and environmental conditions. At each site, the following materials were grown in
a randomised complete block design with four replicates: soybean DAS-81419-2, the conventional
counterpart and three non-GM soybean reference varieties; all treated (sprayed) with required
maintenance pesticides (including conventional herbicides) according to local requirements. In total,
nine non-GM soybean reference varieties14 were included across all the ﬁeld trials sites.
Soybean DAS-81419-2 was obtained using the non-GM soybean variety Maverick as recipient
variety (see Section 3.1.1.1). As documented by the pedigree, the line of soybean DAS-81419-2 used
in the ﬁeld trials was not crossed with other soybean lines. Maverick was used as comparator in the
ﬁeld trials (Table 2), and has the same genetic background as the line of soybean DAS-81419-2. The
GMO Panel considers that this non-transgenic line is the appropriate conventional counterpart.
Statistical analysis of ﬁeld trials data
The statistical analysis of the agronomic, phenotypic and compositional data from the 2011 and
2012 ﬁeld trials followed the recommendations of the GMO Panel (EFSA GMO Panel, 2010b, 2011a).
This includes the application of a difference test (between the GM soybean and its conventional
counterpart) and an equivalence test (between the GM soybean and the set of non-GM commercial
reference varieties). The results of the equivalence test are categorised into four possible outcomes
(I–IV, ranging from equivalence to non-equivalence).15
3.2.1.2. Agronomic and phenotypic characteristics16
Agronomic and phenotypic characteristics tested under ﬁeld conditions
The agronomic and phenotypic characteristics evaluated on the basis of data collected from the 11
ﬁeld trial sites in the USA in 2011 and 2012 (Table 2) were: early population (stand count), seedling
vigour, days to 50% ﬂowering, disease incidence, insect damage, days to maturity, lodging, plant
height, ﬁnal population (stand count), number of seeds, number of pods, pod shattering, yield and
‘100 seed weight’. Data for four endpoints17 were considered not suitable for a parametric analysis
Table 2: Overview of comparative assessment studies with soybean DAS-81419-2 provided in
application EFSA-GMO-NL-2013-116
Study focus Study details Comparator
Commercial reference
varieties
Agronomic and phenotypic
characteristics; composition
Field trials, 2011 and 2012,
USA (11 locations)
Maverick Nine non-GM varieties
Seed germination Controlled conditions
(warm and cold treatment)
Near-isogenic
non-GM line
None
12 Dossier: Part II – Section A3; additional information: 27/8/2014.
13 The sites in 2011 ﬁeld trials were in Richland, IA; Atlantic, IA; Carlyle, IL; Wyoming, IL; Frankfort, IN; Fisk, MO; La Plata, MO;
York, NE; Brunswick, NE; and Germansville, PA. The site of the 2012 ﬁeld trial was in Sheridan, IN.
14 The non-GM reference varieties were Pioneer 93M62, IL3503, DSR 75213-72, Porter 75148, HiSOY 38C60, Williams 82,
Pioneer 93Y41, L&M 34 and Stine 3099-2.
15 In detail, the four outcomes are: category I (indicating full equivalence to the non-GM reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and
category IV (indicating non-equivalence).
16 Dossier: Part II – Section A3.4; additional information 25/11/2014.
17 Disease incidence, insect damage, lodging and seedling vigour.
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because of the nature of the measurements: for those, differences between the GM soybean and the
conventional counterpart were investigated with the Wilcoxon Signed Rank (WSR) test. Pod shattering
was not analysed statistically because all the values were zero.
Statistically signiﬁcant differences were identiﬁed between soybean DAS-81419-2 and its
conventional counterpart for the endpoints days to 50% ﬂowering, early stand count, plant height,
number of pods, number of seeds, ‘100 seed weight’ and yield. Except for ‘100 seed weight’, all the
endpoints fell within the equivalence limits established by the non-GM reference varieties (equivalence
category I). For the endpoint ‘100 seed weight’ equivalence was more likely than non-equivalence
(equivalence category II). The endpoint ‘ﬁnal population’ was not categorised for equivalence due to
the small variation among the non-GM reference varieties, however, it was found not signiﬁcantly
different from the conventional counterpart. Within the endpoints analysed with the WSR test,
statistically signiﬁcant differences were identiﬁed for plant lodging and seedling vigour; however, in
both cases the mean values for the GM soybean were within the range of the non-GM reference
varieties.
Agronomic and phenotypic characteristics tested under controlled conditions18
Seed germination of soybean DAS-81419-2 was compared with that of its near-isogenic non-GM
line under warm and cold conditions. Four replicates of 100 seeds for each line, in a complete
randomised design, were tested for each of the temperature treatments. The warm treatment
consisted of exposure of the seeds to a constant temperature of 25°C for 5 days, while the cold
treatment consisted of exposure to 10°C for 7 days followed by exposure to 25°C for 5 days. The
germination rate of soybean DAS-81419-2 seeds under warm and cold conditions did not differ
signiﬁcantly from that of its conventional counterpart.
3.2.1.3. Compositional analysis19
Soybean forage and seeds harvested from the ﬁeld trials in the USA in 2011 and 2012 (Table 2)
were analysed for 87 different constituents (9 in forage and 78 in seed), including the key constituents
recommended by the OECD (OECD, 2001).20 For 17 seed constituents,21 more than 50% of the
observations were below the limit of quantiﬁcation. The statistical analysis was applied to the
remaining 70 constituents (9 in forage22 and 61 in seed23).
For four seed endpoints,24 equivalence could not be determined because of the small variation
among the non-GM reference varieties. Three of those endpoints were found signiﬁcantly different
between soybean DAS-81419-2 and the conventional counterpart and were further considered
(Table 3).
The combination of test of difference and test of equivalence could be applied to the remaining 66
endpoints. Statistically signiﬁcant differences between soybean DAS-81419-2 and the conventional
counterpart were identiﬁed for 23 of the endpoints (ash in forage and 22 seed endpoints25). All the
endpoints fell under equivalence category I except linoleic acid (18:2) which fell under category
IV (Table 3).
18 Additional information: 27/8/2014.
19 Dossier: Part II – Section A3 and study 130989; additional information: 25/11/2014, 24/11/2015, 7/3/2016, 13/6/2016 and
1/9/2016.
20 The applicant showed that the method used for the analysis of lectin levels was reliable in quantifying relative changes in
levels. Additional information: 7/3/2016, 13/6/2016 and 1/9/2016.
21 Sodium, b-carotene, b-tocopherol and the fatty acids caprylic (8:0), capric (10:0), lauric (12:0), myristic (14:0), myristoleic
(14:1), pentadecanoic (15:0), pentadecenoic (15:1), palmitoleic (16:1), heptadecanoic (17:0), heptadecenoic (17:1),
c-linolenic (18:3), eicosadienoic (20:2), eicosatrienoic (20:3) and arachidonic (20:4).
22 The forage constituents included proximates (protein, fat, ash, moisture and carbohydrates), ﬁbre (acid detergent ﬁbre (ADF)
and neutral detergent ﬁbre (NDF)) and minerals (calcium and phosphorus).
23 The seed constituents included proximates (protein, fat, ash, moisture and carbohydrates), ﬁbre (ADF, NDF and total dietary
ﬁbre), amino acids (alanine, lysine, arginine, methionine, aspartic acid, phenylalanine, cystine, proline, glutamic acid, serine,
histidine, tryptophan, leucine, valine, isoleucine, tyrosine, glycine and threonine), fatty acids (palmitic (16:0), stearic (18:0),
oleic (18:1), linoleic (18:2), linolenic (18:3), arachidic (20:0), eicosenoic (20:1) and behenic (22:0)), vitamins (ascorbic acid,
thiamine HCl, riboﬂavin, niacin, pantothenic acid, pyridoxine HCl, folic acid, a-tocopherol, c-tocopherol and d-tocopherol),
minerals (calcium, copper, iron, magnesium, manganese, phosphorus, potassium, selenium and zinc) and other compounds
(total daidzein equivalent, total genistein equivalent, total glycitein equivalent, lectin, phytic acid, rafﬁnose, stachyose and
trypsin inhibitor).
24 Selenium, aspartic acid, lysine and eicosenoic acid (20:1).
25 Ash, crude protein, moisture, total fat, phenylalanine, palmitic acid (16:0), oleic acid (18:1), linoleic acid (18:2), linolenic acid
(18:3), arachidic acid (20:0), behenic acid (22:0), phosphorus, potassium, zinc, thiamine HCl, niacin, pantothenic acid,
ascorbic acid, a-tocopherol, c-tocopherol, d-tocopherol and total glycitein equivalent.
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The GMO Panel assessed all the compositional differences between soybean DAS-81419-2 and its
conventional counterpart. After considering the well-known biological role of the compounds and the
magnitude of the changes observed, the GMO Panel did not identify any need for further food/feed
safety assessment.
3.2.2. Conclusion on comparative analysis
The GMO Panel concludes that none of the differences identiﬁed in forage and seed composition
between soybean DAS-81419-2 and its conventional counterpart, and none of those identiﬁed in the
agronomic and phenotypic characteristics, needs further assessment regarding food and feed safety.
Based on the agronomic and phenotypic characteristics of soybean DAS-81419-2 tested under ﬁeld
conditions, none of the differences identiﬁed between soybean DAS-81419-2 and its conventional
counterpart requires further assessment, except for ‘100 seed weight’. Additionally, no relevant
differences were observed between soybean DAS-81419-2 and its conventional counterpart with
regard to seed germination tested under controlled conditions. The difference observed in ‘100 seed
weight’ between soybean DAS-81419-2 and its conventional counterpart is further assessed for its
potential environmental impact in Section 3.4.1.1.
3.3. Food/feed safety assessment
3.3.1. Evaluation of relevant scientiﬁc data
3.3.1.1. Effect of processing26
Processed products
Based on the outcome of the comparative assessment, processing of soybean DAS-81419-2 into
food and feed products is not expected to result in products being different from those of commercial
non-GM soybean varieties.
Newly expressed proteins
The effect of heat treatment on Cry1F and Cry1Ac has been previously assessed by the GMO
Panel (EFSA GMO Panel, 2010c). It was showed that Cry1F and Cry1Ac lost their insecticidal activity in
a bioassay after being heated at 75 and 90°C and at pH = 7.5 for 30 min. In the context of this
application, PAT protein solutions were heated (25–95°C) for 30 min. The PAT protein lost 99% of its
enzymatic activity at ≥ 55°C, and 91% of its immunoreactivity at temperatures ≥ 37°C.
3.3.1.2. Toxicology
Toxicological assessment of newly expressed proteins27
The three proteins (Cry1F, Cry1Ac and PAT) newly expressed in soybean DAS-81419-2 have been
extensively characterised and showed the expected molecular weight, immunoreactivity vs speciﬁc
Table 3: Compositional endpoints from seed that are further considered based on the results of the
statistical analysis: means (for the conventional counterpart and the GM soybean) and
equivalence limits (from the non-GM reference varieties) estimated from the 2011 and
2012 ﬁeld trials (Table 2)
Endpoint
Soybean
DAS-81419-2
Conventional
counterpart
Equivalence limits from
non-GM reference varieties
Aspartic acid (% AA) 11.49* 11.52 –
Lysine (% AA) 6.426* 6.312 –
Linoleic acid (18:2) (% FA) 53.92* 54.23 (54.69, 56.84)
Eicosenoic acid (20:1) (% FA) 0.1197* 0.1323 –
For the GM soybean, signiﬁcantly different entries are marked with an asterisk, while the outcomes of the test of equivalence are
differentiated by greyscale backgrounds: white (the equivalence test was not performed) and dark grey (equivalence category IV).
% AA: percentage of total amino acids; % FA: percentage of total fatty acids; –: test of equivalence not applied due to the small
variation among the non-GM reference varieties.
26 Dossier: Part II – Section A3.5.
27 Dossier: Part II – Section A4.2; additional information 17/6/2016.
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antibodies, amino acid sequence and functional activity (Section 3.1.1.3). Cry1F and Cry1Ac are delta-
endotoxins with highly speciﬁc insecticidal properties. These proteins act through cellular receptors found
in target insect species and it is reported that the gastrointestinal tract of mammals, including humans,
lacks receptors with speciﬁc high afﬁnity to Cry proteins (Hammond et al., 2013; Koch et al., 2015). The
same Cry1F and Cry1Ac proteins and the PAT protein have been previously assessed by the GMO
Panel (e.g. EFSA, 2007; EFSA GMO Panel, 2010c, 2011c) and no safety concerns for humans and animals
were identiﬁed in the context of the applications assessed. Updated bioinformatic studies conﬁrmed the
absence of relevant similarities between these newly expressed proteins to known toxins (Section 3.1.1.2).
The applicant provided studies on Cry1F, Cry1Ac and PAT proteins from bacterial recombinant
systems, which were considered equivalent to the plant-produced proteins (Section 3.1.1.3).
In vitro degradation studies28
The resistance to degradation by pepsin of the bacterial Cry1F, Cry1Ac and PAT proteins was
investigated in solutions at pH ~ 1.2 in three independent studies. The studies on Cry1F and Cry1Ac have
been previously assessed by the GMO Panel (EFSA GMO Panel, 2010c). In the context of the application
EFSA-GMO-NL-2013-116, the applicant provided a study on the PAT protein where its integrity in samples
of the incubation mixture taken at various time points was analysed by SDS-PAGE gel electrophoresis
followed by protein staining or by western blotting. The PAT protein was degraded by pepsin within 1 min.
Acute oral toxicity testing29
A mixture of Cry1F and Cry1Ac proteins given to mice by gavages in amounts of 375 and 350 mg/kg
body weight, respectively, did not induce effects attributable to the Cry proteins, neither did PAT
administered at a single dose of 5,000 mg/kg. These studies have been previously assessed by the
EFSA GMO Panel (2010c). In the context of this application, the applicant provided additional acute oral
toxicity studies in mice, respectively, on a Cry1F protein at 300 mg/kg body weight; on a Cry1Ac protein
at 700 mg/kg; and on a PAT protein at 2,000 mg/kg body weight. No effects attributable to these
proteins were seen. The GMO Panel considers acute toxicity testing of the newly expressed proteins of
little additional value to the risk assessment of the repeated human and animal consumption of food
and feed derived from GM plants (EFSA GMO Panel, 2011a).
Toxicological assessment of components other than newly expressed proteins
Soybean DAS-81419-2 did not show any compositional difference to its conventional counterpart
that would require further assessment (Section 3.2.1.3). No further food and feed safety assessment
of components other than newly expressed proteins is required.
Animal studies with the food/feed derived from GM plants
No animal studies with food/feed derived from soybean DAS-81419-2 were provided by the applicant
(e.g. 90-day toxicity studies in rodents or feeding studies in young rapidly growing animal species).
No substantial modiﬁcations in the composition of the food/feed derived from soybean DAS-81419-2
(see Section 3.2.1.3) were noted and no indication of possible unintended effects requiring further
assessment were identiﬁed. Therefore, no animal studies on the food/feed derived from soybean
DAS-81419-2 are required for the assessment of food/feed derived from soybean DAS-81419-2
(EFSA GMO Panel, 2011a).
3.3.1.3. Allergenicity
The strategies to assess the potential risk of allergenicity focus on the source of the recombinant
protein, on the potential of the newly expressed protein to induce sensitisation or to elicit allergic
reactions in already sensitised persons and on whether the transformation may have altered the
allergenic properties of the modiﬁed plant.
Assessment of allergenicity of the newly expressed proteins30
A weight-of-evidence approach was followed, taking into account all of the information obtained on
the newly expressed protein, as no single piece of information or experimental method yield sufﬁcient
evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA GMO Panel, 2011a).
28 Dossier: Part II – Section A5.1; additional information: 17/6/2016.
29 Dossier: Part II – Section A4; additional information: 17/6/2016.
30 Dossier: Part II – Section A5.1, A5.3; additional information: 17/6/2016; 18/1/2016.
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The cry1Fv3 and cry1Ac (synpro) genes originate from B. thuringiensis, while the pat gene originates
from S. viridochromogenes, microorganisms which are not considered to be allergenic sources.
Updated bioinformatic analyses7 of the amino acid sequences of the Cry1F, Cry1Ac and PAT
proteins, using the criterion of 35% identity in a sliding window of 80 amino acids, revealed no
signiﬁcant similarities to known allergens. In addition, the applicant also performed analyses searching
for matches of eight contiguous identical amino acid sequences between the Cry1F, Cry1Ac and PAT
proteins and known allergens, which conﬁrmed the outcome of the previous bioinformatic analysis.
The study on resistance to degradation of the Cry1F, Cry1Ac and PAT proteins by pepsin has been
described in Section 3.3.1.2.
The GMO Panel has previously evaluated the safety of the Cry1F, Cry1Ac and PAT proteins in the
context of previous applications and no concerns on allergenicity were identiﬁed (e.g. EFSA GMO
Panel, 2010c).
Proteins derived from B. thuringiensis (Bt proteins) have been suggested to possess adjuvant
activity, based on animal studies on Cry1Ac (e.g. Vazquez et al., 1999). The Panel has previously
evaluated the safety of the Cry1F and Cry1Ac proteins and no concerns on adjuvanticity in the context
of the applications assessed were identiﬁed (EFSA GMO Panel, 2010c). From the limited experimental
evidence available, the GMO Panel did not ﬁnd indications that the presence of the Bt proteins at the
levels expressed in soybean DAS-81419-2 might act as adjuvants with the potential to enhance a
speciﬁc immunoglobulin E (IgE) response and to favour the development of an allergic reaction.
In the context of the present application, the GMO Panel considers that there are no indications
that the newly expressed Cry1F, Cry1Ac and PAT proteins, individually or their simultaneous presence,
in soybean DAS-81419-2 may be allergenic.
Assessment of allergenicity of the whole GM plant31
Soybean is considered to be a common allergenic food32 (OECD, 2012). Therefore, any potential
change in the endogenous allergenicity of the GM plant when compared with that of its comparator(s)
should be assessed (EFSA GMO Panel, 2011a). The applicant performed in vitro allergenicity studies
using human sera as probes as well as a comparative analysis using measurements of speciﬁc known
soybean allergens in extracts from soybean DAS-81419-2, its conventional counterpart and a set of
non-GM commercial reference soybean varieties.
Initially, the applicant provided one-dimensional electrophoresis followed by western blot and an
inhibition ELISA study using pooled sera from ten individuals allergic to soybean. In addition, the
applicant performed two-dimensional electrophoresis followed by western blot analyses and inhibition
ELISA studies using single sera from six individuals allergic to soybean. On request from the GMO Panel,
the applicant performed a qualitative and quantitative comparative analysis of the two-dimensional
western blots by densitometry. According to the applicant, minor variations in spot intensities, which are
commonly seen in such studies, were observed between soybean DAS-81419-2 and its conventional
counterpart.
Consequently, the applicant spontaneously provided a measurement of speciﬁc known allergens in
soybean by mass spectrometry approaches (i.e. liquid chromatography–mass spectrometry/mass
spectrometry (LC–MS/MS)), which has been previously considered as an alternative/complementary
acceptable approach for the assessment of endogenous allergenicity in GM plants (EFSA GMO Panel,
2010d; Fernandez et al., 2013). The allergens measured by LC–MS/MS were Gly m 1, Gly m 3, Gly m
4, Gly m 5, Gly m 6, Gly m Bd 28 K, Gly m Bd 30 K and Gly m 8 in soybean seeds. The applicant
selected these allergens based on a list of potential soybean allergens described in OECD (2012). The
comparative analysis was performed with the combination of difference and equivalence testing
recommended by the EFSA GMO Panel (2011a). The outcome of such analysis showed that the genetic
modiﬁcation did not induce an over-expression of natural endogenous allergen.
In the context of this application, the GMO Panel considers that there is no evidence that the
genetic modiﬁcation might signiﬁcantly change the overall allergenicity of soybean DAS-81419-2 when
compared with that of its conventional counterpart and non-GM commercial reference soybean
varieties.
31 Dossier: Part II – Section A5.2; additional information 18/1/16.
32 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of
the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC,
Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and
Commission Regulation (EC) No 608/2004.
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3.3.1.4. Nutritional assessment of GM food/feed
The intended trait of soybean DAS-81419-2 is insect resistance, with no intention to alter nutritional
parameters. Comparison of the composition of soybean DAS-81419-2 with its conventional counterpart
and non-GM reference varieties did not identify differences that would require nutritional assessment.
Based on these data, the nutritional value of food and feed derived from soybean DAS-81419-2 is not
expected to differ from that of food and feed derived from non-GM soybean varieties.
3.3.1.5. Post-market monitoring of GM food/feed
No biologically relevant compositional, agronomic and phenotypic changes were identiﬁed in
soybean DAS-81419-2 when compared with its conventional counterpart. Furthermore, the overall
intake or exposure is not expected to change because of the introduction of soybean DAS-81419-2
into the market. The GMO Panel therefore considers soybean DAS-81419-2 to be as safe as its
conventional counterpart and that post-market monitoring (EFSA GMO Panel, 2011a) of the food/feed
derived from soybean DAS-81419-2 is not necessary.
3.3.2. Conclusion on the food/feed safety assessment
The safety assessment identiﬁed no concerns regarding the potential toxicity and allergenicity of
the proteins Cry1F, Cry1Ac and PAT, expressed in soybean DAS-81419-2, and found no evidence that
the genetic modiﬁcation might signiﬁcantly change the overall allergenicity of soybean DAS-81419-2
when compared with that of its conventional counterpart and non-GM commercial reference soybean
varieties. Based on the outcome of the comparative assessment, the nutritional value of food and feed
derived from soybean DAS-81419-2 is not expected to differ from that of food and feed derived from
non-GM soybean varieties. The GMO Panel concludes that soybean DAS-81419-2 is as safe and
nutritious as its conventional counterpart and non-GM soybean reference varieties tested.
3.4. Environmental risk assessment and monitoring plan
3.4.1. Evaluation of relevant scientiﬁc data
Considering the scope of application EFSA-GMO-NL-2013-116 (which excludes cultivation), the
environmental risk assessment (ERA) of soybean DAS-81419-2 is mainly concerned with: (1) the
exposure of bacteria to recombinant DNA in the gastrointestinal tract of animals fed GM material and
bacteria present in environments exposed to their faecal material (manure and faeces); and (2) the
accidental release into the environment of viable soybean DAS-81419-2 seeds during transportation
and processing (EFSA GMO Panel, 2010a).
3.4.1.1. Environmental risk assessment
Persistence and invasiveness of the GM plant33
Cultivated soybean (G. max (L.) Merr.) is a species in the subgenus Soja of the genus Glycine. The
species originated from eastern Asia and is a highly domesticated crop (Lu, 2005). Cultivated soybean
seeds rarely display any dormancy characteristics and can grow as volunteers in the year after
cultivation only under certain environmental conditions. If volunteers occur, they do not compete well
with the succeeding crop, and can easily be controlled mechanically or chemically (OECD, 2000). The
presence of volunteers of G. max was occasionally reported in some areas of Italy where soybean is
intensively cultivated (Celesti-Grapow et al., 2010). However, soybean seeds usually do not survive
during the winter owing to the absence of a dormancy phase, herbivory, rotting and germination, or
owing to management practices prior to planting the subsequent crop (Owen, 2005). Also, survival of
soybean plants outside cultivation areas is limited mainly by a combination of low competitiveness, the
absence of a dormancy phase, and susceptibility to plant pathogens and cold climatic conditions.
The applicant presented agronomic and phenotypic data on soybean DAS-81419-2 gathered from
ﬁeld trials conducted in soybean growing areas in the USA (Section 3.2.1.2). The data showed relevant
difference in ‘100 seed weight’ which was reduced for soybean DAS-81419-2 seeds. No relevant
differences in the other measured plant characteristics were identiﬁed (Section 3.2.2). Due to the low
survival capacity of soybean, the observed difference in ‘100 seed weight’ is unlikely to change the ﬁtness
(e.g. survival, fecundity, competitiveness) or invasiveness characteristics of soybean DAS-81419-2 plants.
33 Dossier: Part II – Sections E3.1; additional information: 27/8/2014; 25/11/2014.
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As the general characteristics of soybean DAS-81419-2 remain unchanged compared to its
conventional counterpart, it is considered very unlikely that soybean DAS-81419-2 will differ from non-GM
soybean varieties in its ability to survive until subsequent seasons, or to establish occasional feral plants
under European environmental conditions in case of accidental release into the environment of viable
soybean DAS-81419-2 seeds during transportation and processing.
The GMO Panel is not aware of any scientiﬁc report of increased survival capacity, including
overwintering, of existing GM soybeans varieties (Dorokhov et al., 2004; Owen, 2005; Bagavathiannan
and Van Acker, 2008; Lee et al., 2009). Therefore, the GMO Panel is of the opinion that the likelihood
of environmental effects of soybean DAS-81419-2 in Europe will not be different from that of non-GM
soybean varieties.
Effects of gene transfer34
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through HGT of DNA, or through vertical gene ﬂow via cross-pollination from ﬂowering
plants arising from spilled seed.
1) Plant-to-microorganism gene transfer
Genomic plant DNA is a component of several food and feed products derived from soybean. It is
well documented that DNA present in food and feed becomes substantially degraded during processing
and digestion in the human or animal gastrointestinal tract. However, a low level of exposure of
fragments of ingested DNA, including the recombinant fraction of such DNA, to bacteria in the
digestive tract of humans, domesticated animals and other environments exposed to the GM plant or
plant material is expected.
Current scientiﬁc knowledge of recombination processes in bacteria indicates that horizontal
transfer of non-mobile, chromosomally located DNA fragments between unrelated organisms (such as
plants to bacteria) is not likely to occur at detectable frequencies under natural conditions (EFSA,
2009).
A successful HGT would require stable insertion of the recombinant DNA sequences into a bacterial
genome and conferring a selective advantage to the transformed host. The only mechanism known to
facilitate horizontal transfer of non-mobile, chromosomal DNA fragments into bacterial genomes is
homologous recombination. This requires the presence of stretches of DNA sequences that are similar
in the recombining DNA molecules. In addition to substitutive gene replacement, the insertion of
non-homologous DNA sequences is facilitated if their ﬂanking regions share sequence similarity with
bacterial sequences in the recipient.
Soybean event DAS-81419-2 contains several genetic elements of bacterial origin. These are: (1)
the cry1Fv3 (synthetic version of the cry1F gene from B. thuringiensis subsp. aizawai strain PS811);
(2) the cry1Ac (synpro) (synthetic version of the cry1Ac gene from B. thuringiensis subsp. kurstaki
strain HD73); (3) the pat (synthetic version of phosphinothricin acetyltransferase gene from
S. viridochromogenes) and the (4) three untranslated regions (UTR) two AtuORF23 and one AtuORF1
of A. tumefaciens pTi15955.
Bioinformatic analysis of the inserted DNA conﬁrmed that the plant codon-use optimised bacterial
genes cry1Fv3, cry1Ac (synpro) and pat did not provide sufﬁcient sequence identity to facilitate
homologous recombination. However, sufﬁcient sequence identity with bacterial DNA was found for the
AtuORF23 30 sequence, that ﬂanks the cry1Ac (synpro) gene, and for AtuORF23 and AtuORF1, ﬂanking
the pat gene, both occurring on the A. tumefaciens plasmid pTi15955. Double homologous
recombination of transgenic plant DNA with plasmid DNA of A. tumefaciens could result in an insertion
of the cry1Ac (synpro) at the AtuORF23 site and an insertion of the pat gene into the region between
AtuORF23 and AtuORF1.
A. tumefaciens occurs in soil, water and in the plant rhizosphere. It is therefore not expected to be
prevalent in the main receiving environments, i.e. the gastrointestinal tract of humans or animals.
However, occurrence of the recombinant genes outside of the immediate receiving environment
(through faecal material) in soils cannot be ruled out, and is therefore also considered when assessing
the risks associated with a HGT.
As indicated above, there is a theoretical possibility of double homologous recombination resulting in
a plasmid with the codon-optimised cry1Ac (synpro) gene or pat gene, both under the control of a plant
viral CsVMV promoter, in A. tumefaciens. Such recombination event, however, is expected to be
34 Dossier: Part II – Section E3.1; 3.2.
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expressed at low levels by the plant viral promoter. Compared to the natural bacterial variants of these
genes, it is likely that the plant-optimised genes will result in less functional proteins in bacteria. The
acquisition of the cry1Ac (synpro) and pat gene is unlikely to confer a selective advantage to
A. tumefaciens in their natural habitats except when the pat gene changes the sensitivity to glufosinate
ammonium when it is applied. The insertion of the pat gene on the Ti plasmid would result in a
dysfunctional plasmid due to the loss of a large fragment between AtuORF23 and AtuORF1. The
theoretical potential of recombinant Ti-plasmids to transfer the recombinant genes from A. tumefaciens
back to infected plants would be limited to the infected tissue (crown gall tumour) and not enter the
germline. For the pat gene insertion the Ti plasmid would lose its potential for crown gall formation, due
to the loss of plasmid encoded genes between AtuORF23 and AtuORF1.
In addition to homology-based recombination processes, non-homologous (illegitimate) recombination
that does not require DNA similarity between the recombining DNA molecules is theoretically possible.
However, illegitimate recombination events have not been detected in studies that have exposed
bacteria to high concentrations of GM plant DNA (EFSA, 2009). Thus, this process, in comparison with
homologous recombination, is not considered to contribute signiﬁcantly to HGT events.
In summary, the GMO Panel identiﬁed two theoretical scenarios where recombinant genes could be
transferred by double homologous recombination onto a plasmid of a soil bacterium. The transfer
would, however, not provide an immediate selective advantage to the recipient bacteria, except for
glufosinate ammonium. Considering the occurrence of natural variants of cry and pat genes in
environmental bacterial communities, such recombinant genes would not introduce new properties to
the environment. Therefore, the GMO Panel did not identify a concern in relation to the theoretically
possible horizontal transfer of recombinant genes from DAS-81419-2 to bacteria.
2) Plant-to-plant gene transfer
Considering the scope of the application EFSA-GMO-NL-2013-116 and the biology of soybean, the
potential of occasional feral GM soybean plants originating from seed import spills to transfer
recombinant DNA to sexually cross-compatible plants is assessed.
The genus Glycine is divided into two distinct subgenera: Glycine and Soja. The subgenus Glycine
contains 16 perennial wild species, while the cultivated soybean, G. max, and its wild and semiwild
annual relatives, G. soja and G. gracilis, are classiﬁed in the subgenus Soja (OECD, 2000). Owing to the
low level of genomic similarity among species of the genus Glycine, G. max can cross with only other
members of the Glycine subgenus Soja under natural conditions (Singh et al., 1987; Hymowitz et al.,
1998; Lu, 2005). Hence, the three species of the subgenus Soja are capable of cross-pollination and the
hybrid seed that is produced can germinate normally and produce plants with fertile pollen and seed
(Abe et al., 1999; Nakayama and Yamaguchi, 2002). Since G. soja and G. gracilis are indigenous to
China, Taiwan, Korea, Japan, the far-east region of Russia, Australia, the Philippines and the South
Paciﬁc, and since they have not been reported in other parts of the world where the cultivated soybean
is grown (Dorokhov et al., 2004; Lu, 2005), the plant-to-plant gene transfer from soybean is restricted
to cultivated areas and occasional soybean plants resulting from seed spillage in the EU.
Soybean is an annual, almost completely self-pollinating crop with a percentage of cross-pollination
usually below 1% (OECD, 2000; Ray et al., 2003; Lu, 2005; Yoshimura et al., 2006; Abud et al., 2007).
Soybean pollen dispersal is limited because the anthers mature in the bud and directly pollinate the
stigma of the same ﬂower (OECD, 2000).
However, cross-pollination rates as high as 6.3% have been reported for closely spaced plants
(Ray et al., 2003), suggesting the potential for some within-crop gene ﬂow in soybean. These results
indicate that natural cross-pollination rates can ﬂuctuate signiﬁcantly among different soybean varieties
under particular environmental conditions, such as favourable climate for pollination and an abundance
of pollinators (Gumisiriza and Rubaihayo, 1978; Kikuchi et al., 1993; Ahrent and Caviness, 1994;
Ray et al., 2003; Lu, 2005).
For plant-to-plant gene transfer to occur, imported soybean DAS-81419-2 seeds need to be
processed outside the importing ports, transported into regions of soybean production in Europe,
spilled during transportation, germinate and develop into plants in the very close vicinity of soybean
ﬁelds, and there needs to be an overlap of ﬂowering periods and environmental conditions favouring
cross-pollination. It must be noted that most soybean DAS-81419-2 seeds are processed in the
countries of production or in ports of importation. The overall likelihood of cross-pollination between
occasional feral GM soybean plants and cultivated soybean is therefore extremely low.
In conclusion, even if cross-pollination would occur, the GMO Panel is of the opinion that the
likelihood of environmental effects as a consequence of the spread of genes from occasional feral GM
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soybean plants in Europe will not differ from that of conventional soybean varieties (see previous
Section 3.4.1.1).
Interactions of the GM plant and target organisms35
Considering the scope of the application EFSA-GMO-NL-2013-116, potential interactions of
occasional feral soybean DAS-81419-2 plants arising from seed import spills with target organisms are
not considered a relevant issue by the GMO Panel.
Interactions of the GM plant with non-target organisms36
Considering that environmental exposure of non-target organisms to stored GM seeds, spilled GM
seeds or GM plants arising from spilled GM seeds is limited, potential exposure of non-target
organisms sensitive to Cry1Ac and/or Cry1F proteins is likely to be very low and of no relevance.
The GMO Panel evaluated whether the expressed Cry1Ac and Cry1F proteins might potentially
affect non-target organisms by entering the environment through faecal material of animals fed GM
soybean. Cry proteins are degraded by enzymatic activity in the gastrointestinal tract, meaning that
only low amounts of intact Cry proteins would remain in the faeces. This was demonstrated for Cry1Ab
(Einspanier et al., 2004; Lutz et al., 2005, 2006; Wiedemann et al., 2006; Guertler et al., 2008; Paul
et al., 2010). Further degradation of the protein in the manure and faeces will take place because of
microbiological proteolytic activity. In addition, there will be further degradation of Cry proteins in soil,
reducing the possibility for exposure of potentially sensitive non-target organisms. Although Cry
proteins may bind to clay minerals and organic substances in soil, thereby reducing their availability to
microorganisms for degradation, there are no indications of persistence and accumulation of Cry
proteins from GM crops in soil (Gruber et al., 2011; Valldor et al., 2015). The GMO Panel is not aware
of evidence of released Cry proteins from GM plants causing signiﬁcant negative effects on soil
microorganisms.
Considering the scope of the application, it can be concluded that the exposure of potentially
sensitive non-target organisms to the Cry1Ac and Cry1F proteins is likely to be very low and of no
biological relevance, regardless of potential synergistic interactions that might occur between the
different Cry proteins.
Interactions with the abiotic environment and on biogeochemical cycles37
Considering the scope of the application EFSA-GMO-NL-2013-116, and the low level of exposure to
the environment, potential interactions of occasional feral soybean DAS-81419-2 plants arising from
seed import spills with the abiotic environment and biogeochemical cycles are not considered a
relevant issue by the GMO Panel.
3.4.2. Post-market environmental monitoring38
The objectives of a PMEM plan, according to Annex VII of Directive 2001/18/EC are to: (1) conﬁrm
that any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or
its use, in the ERA are correct; and (2) identify the occurrence of adverse effects of the GMO, or its
use, on human health or the environment that were not anticipated in the ERA.
Monitoring is related to risk management, and thus a ﬁnal adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientiﬁc content of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
The PMEM plan proposed by the applicant includes: (1) the description of a monitoring approach
involving operators (federations involved in soybean import and processing), reporting to the
applicants, via a centralised system, any observed adverse effect(s) of GMOs on human health and the
environment; (2) a coordinating system established by EuropaBio for the collection of information
recorded by the various operators (Lecoq et al., 2007; Windels et al., 2008); and (3) the use of
networks of existing surveillance systems. The applicant proposes to submit a PMEM report on an
annual basis, and a ﬁnal report at the end of the consent period. The GMO Panel considers that the
scope of the PMEM plan provided by the applicant is consistent with the scope of soybean DAS-81419-2.
As the ERA does not cover cultivation and did not identify potential adverse environmental effects from
35 Dossier: Part II – Section E3.3.
36 Dossier: Part II – Section E3.4.
37 Dossier: Part II – Section E3.6.
38 Dossier: Part II – Section E4; additional information: 27/8/2014.
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soybean DAS-81419-2, no case-speciﬁc monitoring is necessary. The GMO Panel agrees with the
reporting intervals proposed by the applicant in its PMEM plan.
3.4.3. Conclusion on the environmental risk assessment and monitoring plan
In the case of accidental release into the environment of viable seeds of soybean DAS-81419-2,
there are no indications of an increased likelihood of establishment and spread of occasional feral
soybean DAS-81419-2 plants, unless these plants are exposed to glufosinate ammonium-based
herbicides or infested by insect pests that are susceptible to the Cry1F and Cry1Ac proteins. The GMO
Panel is of the opinion that this will not result in different environmental impacts compared to
conventional soybean.
Considering the scope of the application EFSA-GMO-NL-2013-116, interactions of soybean
DAS-81419-2 with the biotic and abiotic environment are not considered to be relevant issues.
Bioinformatic analysis of the inserted DNA identiﬁed sufﬁcient sequence identity with bacterial DNA
which could theoretically facilitate the transfer of a plant codon-optimised cry gene and a pat gene
onto a plasmid of a soil bacterium. Considering the occurrence of natural variants of such genes in
environmental bacterial communities, the GMO panel did not identify a concern in relation to the
theoretically possible HGT to bacteria.
Therefore, considering the introduced traits, the outcome of the comparative analysis, the routes of
exposure and the limited exposure levels, the GMO Panel concludes that soybean DAS-81419-2 would
not raise safety concerns in the event of accidental release of viable GM soybean seeds into the
environment.
The scope of the PMEM plan provided by the applicant and the reporting intervals are in line with
the intended uses of soybean DAS-81419-2 and the GMO Panel guidelines on the PMEM of GM plants
(EFSA GMO Panel, 2011b).
4. Conclusions
The EFSA GMO Panel was asked to carry out a scientiﬁc assessment of soybean DAS-81419-2 for
import, processing, and food/feed uses in accordance with Regulation (EC) No 1829/2003. The
molecular characterisation data provided for soybean DAS-81419-2 did not give rise to safety issues.
The GMO Panel concluded that none of the differences identiﬁed in the compositional, agronomic and
phenotypic characteristics of soybean DAS-81419-2 required further assessment regarding food and
feed safety. No concerns regarding the potential toxicity or allergenicity of the newly expressed Cry1F,
Cry1Ac and the PAT proteins were identiﬁed, and no evidence that the genetic modiﬁcation might
signiﬁcantly change the overall allergenicity of soybean DAS-81419-2 was found. The nutritional value
of food and feed derived from soybean DAS-81419-2 is not expected to differ from that of food and
feed derived from non-GM soybean varieties. The GMO Panel concludes that soybean DAS-81419-2,
assessed in this application, is as safe and nutritious as its conventional counterpart and the non-GM
soybean reference varieties tested. The GMO Panel concluded that there is a very low likelihood of
environmental effects resulting from the accidental release of viable seeds from soybean DAS-81419-2
into the environment. Considering the scope of the application with regard to food and feed use,
interactions with the biotic and abiotic environment were not considered an issue. Risks associated
with an unlikely, but theoretically possible, HGT from soybean DAS-81419-2 to bacteria have not been
identiﬁed. The scope of the PMEM plan provided by the applicant is in line with the intended uses of
soybean DAS-81419-2.
In conclusion, the GMO Panel considers that the information available for soybean DAS-81419-2
addresses the scientiﬁc comments raised by the Member States and that the soybean DAS-81419-2, as
described in this application, is as safe and nutritious as its conventional counterpart and non-GM
reference varieties tested with respect to potential effects on human and animal health and the
environment in the context of the scope of the application.
Documentation provided to EFSA
1) Letter from the Competent Authority of the Netherlands, received on 13 May 2013, concerning
a request for placing on the market of soybean DAS-81419-2 submitted in accordance with
Regulation (EC) No 1829/2003 by Dow AgroSciences (EFSA-GMO-NL-2013-116).
2) Acknowledgement letter dated 7 June 2103 from EFSA to the Competent Authority of the
Netherlands.
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3) Letter from EFSA to applicant dated 25 June 2013 requesting additional information under
completeness check.
4) Letter from applicant to EFSA received on 21 November 2013 providing additional
information under completeness check.
5) Letter from EFSA to applicant dated 12 December 2013 requesting additional information
under completeness check.
6) Letter from applicant to EFSA received on 17 January 2014 providing additional information
under completeness check.
7) Letter from EFSA to applicant dated 7 February 2014 delivering the ‘Statement of Validity’ for
application EFSA-GMO-NL-2013-116, soybean DAS-81419-2 submitted by Dow AgroSciences
under Regulation (EC) No 1829/2003.
8) Letter from EFSA to applicant dated 12 February 2014 requesting additional information and
stopping the clock on behalf of the EURL-GMFF.
9) Letter from EFSA to applicant dated 21 March 2014 re-starting the clock on behalf of the
EURL-GMFF.
10) Letter from EFSA to applicant dated 8 April 2014 requesting additional information and
stopping the clock.
11) Letter from EFSA to applicant dated 28 May 2014 requesting additional information and
maintaining the clock stopped.
12) Letter from applicant to EFSA received on 18 June 2014 providing additional information.
13) Letter from EFSA to applicant dated 23 June 2014 requesting additional information and
maintaining the clock stopped.
14) Letter from applicant to EFSA received on 27 August 2014 providing additional information.
15) Letter from EFSA to applicant dated 9 September 2014 requesting additional information and
maintaining the clock stopped.
16) Letter from applicant to EFSA received on 12 November 2014 providing additional
information.
17) Letter from applicant to EFSA received on 25 November 2014 providing additional
information.
18) Letter from applicant to EFSA received on 16 December 2014 providing additional
information spontaneously.
19) Letter from EFSA to applicant dated 1 October 2015 requesting additional information and
maintaining the clock stopped.
20) Letter from EFSA to applicant dated 9 November 2015 annulling the question sent on 1
October 2015.
21) Letter from EFSA to applicant dated 23 November 2015 requesting additional information
and maintaining the clock stopped.
22) Letter from applicant to EFSA received on 24 November 2015 providing additional
information.
23) Letter from applicant to EFSA received on 18 January 2016 providing additional information.
24) Letter from applicant to EFSA received on 22 January 2016 providing clariﬁcations on the
scope of the application.
25) Letter from EFSA to applicant dated 11 February 2016 re-starting the clock.
26) Letter from EFSA to applicant dated 17 February 2016 requesting additional information and
stopping the clock.
27) Letter from applicant to EFSA received on 7 March 2016 providing additional information.
28) Email from EFSA to applicant dated 10 March 2016 re-starting the clock from 7 March 2016.
29) Letter from EFSA to applicant dated 15 March 2016 requesting additional information and
stopping the clock.
30) Letter from applicant to EFSA received on 29 March 2016 providing additional information.
31) Letter from applicant to EFSA received on 31 March 2016 providing additional information
(sequence information) spontaneously.
32) Letter from EFSA to applicant dated 25 April 2016 requesting additional information and
stopping the clock on behalf of the EURL-GMFF.
33) Letter from EFSA to applicant dated 26 May 2016 requesting additional information and
maintaining the clock stopped.
34) Letter from EFSA to applicant dated 10 June 2016 requesting additional information and
maintaining the clock stopped.
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35) Letter from applicant to EFSA received on 13 June 2016 providing additional information.
36) Letter from applicant to EFSA received on 17 June 2016 providing additional information.
37) Letter from EFSA to applicant dated 10 August 2016 requesting additional information and
maintaining the clock stopped.
38) Letter from applicant to EFSA received on 1 September 2016 providing additional
information.
39) Letter from EURL to EFSA dated 7 September 2016 requesting to re-start the clock.
40) Letter from EFSA to applicant dated 8 September 2016 re-starting the clock.
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